scholarly journals Levels of a subpopulation of platelets, but not circulating endothelial cells, predict early treatment failure in prostate cancer patients after prostatectomy

2012 ◽  
Vol 107 (9) ◽  
pp. 1564-1573 ◽  
Author(s):  
C K E Wong ◽  
B Namdarian ◽  
J Chua ◽  
X Chin ◽  
R Speirs ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Endothelial Cells ◽  
Treatment Failure ◽  
Cancer Patients ◽  
Early Treatment ◽  
Circulating Endothelial Cells ◽  
Early Treatment Failure

scholarly journals Serum microRNA expression patterns that predict early treatment failure in prostate cancer patients

Oncotarget ◽  
2014 ◽  
Vol 5 (3) ◽  
pp. 824-840 ◽  
Author(s):  
Prashant K. Singh ◽  
Leah Preus ◽  
Qiang Hu ◽  
Li Yan ◽  
Mark D. Long ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Treatment Failure ◽  
Cancer Patients ◽  
Early Treatment ◽  
Expression Patterns ◽  
Microrna Expression ◽  
Early Treatment Failure ◽  
Serum Microrna

scholarly journals Increased levels of viable circulating endothelial cells are an indicator of progressive disease in cancer patients

2004 ◽  
Vol 15 (1) ◽  
pp. 139-145 ◽  
Author(s):  
L.V. Beerepoot ◽  
N. Mehra ◽  
J.S.P. Vermaat ◽  
B.A. Zonnenberg ◽  
M.F.G.B. Gebbink ◽  
...  
Keyword(s):  
Endothelial Cells ◽  
Cancer Patients ◽  
Progressive Disease ◽  
Circulating Endothelial Cells

scholarly journals Accuracy of Tumour-Associated Circulating Endothelial Cells as a Screening Biomarker for Clinically Significant Prostate Cancer

Cancers ◽  
2019 ◽  
Vol 11 (8) ◽  
pp. 1064 ◽  
Author(s):  
Sebastian Chakrit Bhakdi ◽  
Prapat Suriyaphol ◽  
Ponpan Thaicharoen ◽  
Sebastian Tobias Karl Grote ◽  
Chulaluk Komoltri ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Endothelial Cells ◽  
Predictive Value ◽  
Specific Antigen ◽  
Transrectal Ultrasound ◽  
Circulating Endothelial Cells ◽  
Index Test ◽  
Psa Testing ◽  
Diagnostic Potential ◽  
Clinically Significant

Even though more than 350,000 men die from prostate cancer every year, broad-based screening for the disease remains a controversial topic. Guidelines demand that the only commonly accepted screening tool, prostate-specific antigen (PSA) testing, must be followed by prostate biopsy if results are elevated. Due to the procedure’s low positive predictive value (PPV), however, over 80% of biopsies are performed on healthy men or men with clinically insignificant cancer—prompting calls for new ways of vetting equivocal PSA readings prior to the procedure. Responding to the challenge, the present study investigated the diagnostic potential of tumour-associated circulating endothelial cells (tCECs), which have previously been described as a novel, blood-based biomarker for clinically significant cancers. Specifically, the objective was to determine the diagnostic accuracy of a tCEC-based blood test to detect clinically significant prostate cancer (defined as Gleason score ≥ 3 + 4) in high-risk patients. Performed in a blinded, prospective, single-centre set-up, it compared a novel tCEC index test with transrectal ultrasound-guided biopsy biopsy as a reference on a total of 170 patients and found that a tCEC add-on test will almost double the PPV of a standalone PSA test (32% vs. 17%; p = 0.0012), while retaining a negative predictive value above 90%.

411 THE POTENTIAL OF CIRCULATING ENDOTHELIAL CELLS AS PROGNOSTIC BIOMARKERS IN PROSTATE CANCER

2011 ◽  
Vol 10 (2) ◽  
pp. 143
Author(s):  
B. Namdarian ◽  
H.D. Georgiou ◽  
J. Chua ◽  
X. Chin ◽  
M.K.H. Hong ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Endothelial Cells ◽  
Prognostic Biomarkers ◽  
Circulating Endothelial Cells

scholarly journals Mycobacterium abscessus Complex Infections: A Retrospective Cohort Study

2018 ◽  
Vol 5 (2) ◽  
Author(s):  
Maroun Sfeir ◽  
Marissa Walsh ◽  
Rossana Rosa ◽  
Laura Aragon ◽  
Sze Yan Liu ◽  
...  
Keyword(s):  
Risk Factors ◽  
Cohort Study ◽  
Renal Disease ◽  
Treatment Failure ◽  
Retrospective Cohort Study ◽  
Early Treatment ◽  
Retrospective Cohort ◽  
Positive Culture ◽  
Mycobacterium Abscessus ◽  
Early Treatment Failure

Abstract Background Infections caused by Mycobacterium abscessus group strains are usually resistant to multiple antimicrobials and challenging to treat worldwide. We describe the risk factors, treatment, and clinical outcomes of patients in 2 large academic medical centers in the United States. Methods A retrospective cohort study of hospitalized adults with a positive culture for M. abscessus in Miami, Florida (January 1, 2011, to December 31, 2014). Demographics, comorbidities, the source of infection, antimicrobial susceptibilities, and clinical outcomes were analyzed. Early treatment failure was defined as death and/or infection relapse characterized either by persistent positive culture for M. abscessus within 12 weeks of treatment initiation and/or lack of radiographic improvement. Results One hundred eight patients were analyzed. The mean age was 50.81 ± 21.03 years, 57 (52.8%) were females, and 41 (38%) Hispanics. Eleven (10.2%) had end-stage renal disease, 34 (31.5%) were on immunosuppressive therapy, and 40% had chronic lung disease. Fifty-nine organisms (54.6%) were isolated in respiratory sources, 21 (19.4%) in blood, 10 (9.2%) skin and soft tissue, and 9 (8.3%) intra-abdominal. Antimicrobial susceptibility reports were available for 64 (59.3%) of the patients. Most of the isolates were susceptible to clarithromycin, amikacin, and tigecycline (93.8%, 93.8%, and 89.1%, respectively). None of the isolates were susceptible to trimethoprim/sulfamethoxazole, and only 1 (1.6%) was susceptible to ciprofloxacin. Thirty-six (33.3%) patients early failed treatment; of those, 17 (15.7%) died while hospitalized. On multivariate analysis, risk factors significantly associated with early treatment failure were disseminated infection (odds ratio [OR], 11.79; 95% confidence interval [CI], 1.53–81.69; P = .04), acute kidney injury (OR, 6.55; 95% CI, 2.4–31.25; P = .018), organ transplantation (OR, 2.37; 95% CI, 2.7–23.1; P = .005), immunosuppressive therapy (OR, 2.81; 95% CI, 1.6–21.4; P = .002), intravenous amikacin treatment (OR, 4.1; 95% CI, 0.9–21; P = .04), clarithromycin resistance (OR,79.5; 95% CI, 6.2–3717.1, P < .001), and presence of prosthetic device (OR, 5.43; 95% CI, 1.57–18.81; P = .008). Receiving macrolide treatment was found to be protective against early treatment failure (OR, 0.13; 95% CI, 0.002–1.8; P = .04). Conclusions Our cohort of 108 M. abscessus complex isolates in Miami, Florida, showed an in-hospital mortality of 15.7%. Most infections were respiratory. Clarithromycin and amikacin were the most likely agents to be susceptible in vitro. Resistance to fluoroquinolone and trimethoprim/sulfamethoxazole was highly common. Macrolide resistance, immunosuppression, and renal disease were significantly associated with early treatment failure.

scholarly journals Predictors of recurrence, early treatment failure and death from Staphylococcus aureus bacteraemia: Observational analyses within the ARREST trial

2019 ◽  
Vol 79 (4) ◽  
pp. 332-340 ◽  
Author(s):  
Alexander Szubert ◽  
Sarah Lou Bailey ◽  
Graham S. Cooke ◽  
Tim Peto ◽  
Martin J. Llewelyn ◽  
...  
Keyword(s):  
Staphylococcus Aureus ◽  
Treatment Failure ◽  
Early Treatment ◽  
Early Treatment Failure ◽  
Predictors Of Recurrence

Elevated Pretreatment CEA and CA19-9 Levels are Related to Early Treatment Failure in Esophageal Adenocarcinoma

2019 ◽  
Vol 42 (4) ◽  
pp. 345-350
Author(s):  
Rosa T. van der Kaaij ◽  
Francine E.M. Voncken ◽  
Jolanda M. van Dieren ◽  
Petur Snaebjornsson ◽  
Catharina M. Korse ◽  
...  
Keyword(s):  
Treatment Failure ◽  
Esophageal Adenocarcinoma ◽  
Early Treatment ◽  
Early Treatment Failure
Sign in / Sign up

Export Citation Format

Share Document